Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Aug 2;23(9):16.
doi: 10.1007/s11894-021-00816-3.

Epidemiology of Colorectal Cancer in Inflammatory Bowel Disease - the Evolving Landscape

Elyse A Linson  1 , Stephen B Hanauer  2
Affiliations
Review

Epidemiology of Colorectal Cancer in Inflammatory Bowel Disease - the Evolving Landscape

Elyse A Linson et al. Curr Gastroenterol Rep. .

Abstract

Purpose of review: To update changes in the epidemiology of colorectal cancer in patients with ulcerative colitis and Crohn's disease over the past decades.

Recent findings: Since the mid twentieth century, studies have found that the incidence of colorectal cancer in patients with IBD has been greater than that of the general population, especially for patients with a family history of colorectal cancer, a diagnosis of primary sclerosing cholangitis, and/or pancolitis. While Crohn's disease and ulcerative colitis are still associated with a risk of colorectal cancer, current treatment approaches and surveillance measures have markedly reduced the risk according to population-based cohort studies such that the risk is now more comparable to that of the general population. It is predicted that by 2025, more than two million patients will be living with inflammatory bowel disease in the United States. As advanced treatment options become available to achieve histologic remissions and as surveillance techniques to detect neoplasia improve, guidelines for surveillance will continue to evolve.

Keywords: Colorectal cancer; Crohn’s disease; Epidemiology of colorectal cancer; Inflammatory bowel disease; Risk of colorectal cancer; Ulcerative colitis.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
    1. Ananthakrishnan AN, Cagan A, Gainer VS, Cheng SC, Cai T, Szolovits P, Shaw SY, Churchill S, Karlson EW, Murphy SN, Kohane I, Liao KP. Mortality and extraintestinal cancers in patients with primary sclerosing cholangitis and inflammatory bowel disease. J Crohn’s Colitis. 2014;8:956–63.
    1. Atkinson AJ, Carroll WW. Sclerosing cholangitis. Association with regional enteritis. JAMA. 1964;188:183–4. - PubMed
    1. Bernstein CN, Blanchard JF, Kliewer E, Wajda A. Cancer risk in patients with inflammatory bowel disease: a population-based study. Cancer. 2001;91(4):854–62. - PubMed
    1. Bonovas S, Fiorino G, Lytras T, Nikolopoulos G, Peyrin-Biroulet L, Danese S. Systematic review with meta-analysis: use of 5-aminosalicylates and risk of colorectal neoplasia in patients with inflammatory bowel disease. Aliment Pharmacol Ther. 2017;45:1179–92. - PubMed
    1. Broome U, Lofberg R, Veress B, Eriksson LS. Primary sclerosing cholangitis and ulcerative colitis: evidence for increased neoplastic potential. Hepatology. 1995;22(5):1404–8. - PubMed

MeSH terms

LinkOut - more resources